The effect of baricitinib on pSTAT3 levels in IL-6- or IL-15-stimulated PBMCs isolated from patients with SLE
These findings highlight the cell-type and cytokine-specific effects of baricitinib and demonstrate its capacity to dampen IL-6- and IL-15-mediated STAT3 activation in key immune cell subsets. Our results support a precision medicine approach to JAK inhibition in SLE and reinforce the potential of baricitinib in modulating key inflammatory pathways.
Authors
- Gergely Toldi (ORCID: https://orcid.org/0000-0003-0178-1243)
- Attila Balog (ORCID: https://orcid.org/0000-0003-0899-4655)
- József Á. Balog (ORCID: https://orcid.org/0000-0001-8208-9157)
- Gábor J. Szebeni (ORCID: https://orcid.org/0000-0002-6998-5632)
- Nikolett Gémes (ORCID: https://orcid.org/0000-0003-2028-1666)
- Dániel Honfi
- Patrícia Neuperger
- Enikő Szabó (ORCID: https://orcid.org/0000-0002-7701-8861)
Institutions
- University of Auckland (NZ)
- University of Szeged (HU)
- HUN-REN Szegedi Biológiai Kutatóközpont (HU)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1675350
- Citations
- 1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.67
Funders
- Magyar Tudományos Akadémia
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
- Szegedi Tudományegyetem